# OnCo record onco-reveal-dx-lung-colon (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/onco-reveal-dx-lung-colon/>
  a schema:MedicalTest ;
  onco:kind "drug" ;
  schema:identifier "onco-reveal-dx-lung-colon" ;
  schema:name "ONCO/Reveal Dx Lung and Colon Cancer Assay"@en ;
  schema:alternateName "ONCO/Reveal Dx Lung & Colon Cancer Assay"@en, "O/RDx-LCCA"@en, "ONCO/Reveal Dx Lung & Colon Cancer Assay" ;
  schema:description "A sequencing test that confirms KRAS is unmutated before cetuximab or panitumumab in bowel cancer, and finds common EGFR mutations in lung cancer."@en ;
  schema:url <https://onco.cc/drugs/onco-reveal-dx-lung-colon/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200011>, <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools> ;
  onco:status "approved" ;
  onco:tag "test" ;
  onco:modality "Tissue NGS companion diagnostic test (KRAS and EGFR)" ;
  onco:approval "US 2021: KRAS wild-type for cetuximab or panitumumab in colorectal cancer; EGFR exon 19 deletion or L858R for approved EGFR inhibitors in NSCLC (group labelling)" ;
  onco:related <https://onco.cc/biomarkers/ras-wild-type/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/erlotinib/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/gefitinib/>, <https://onco.cc/drugs/afatinib/>, <https://onco.cc/drugs/dacomitinib/>, <https://onco.cc/drugs/lazertinib/> ;
  onco:companies <https://onco.cc/companies/pillar-biosciences/> ;
  onco:terms <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/companion-diagnostic-term/> .